Crystal Pharmaceutical (Suzhou) Co., Ltd.

Yuhao Chen

Yanfeng Zhang

Minhua Chen

Xiaoyu Zhang

Chaohui Yang

Xiaoting Zhai

Fei Lu

Jiale Qian

Hui Gao

The present disclosure relates to novel crystalline forms of ARN-509 (structure shown in formula I), processes for preparation of the novel crystalline forms, pharmaceutical composition of the novel crystalline forms, and uses of the novel crystalline forms for preparing drug products of androgen receptor antagonists and for treating prostate cancer. The crystalline forms of ARN-509 provided by the present disclosure have one or more improved properties compared with the prior art, and is of great value to the future optimization and development of drugs. 

Crystalline forms of ARN-509, preparation method and use thereof

The present disclosure relates to a novel crystalline form of Galunisertib, processes for preparation and use thereof. The present disclosure also relates to a pharmaceutical composition comprises the novel crystalline form of Galunisertib and use of the novel crystalline form of Galunisertib and pharmaceutical composition for preparing drugs treating disease. The crystalline form of the present disclosure has good stability, solubility and hygroscopicity, which has significant value for future drug optimization and development. 

Galunisertib crystalline form, preparation method thereof and use thereof

Growing community of inventors

Suzhou, China

Yuhao Chen